Back to Search Start Over

Letrozole Induced Hypercalcemia in a Patient with Breast Cancer

Authors :
Suleyman Hilmi Ipekci
Suleyman Baldane
Ercument Ozturk
Murat Araz
Huseyin Korkmaz
Fatih Colkesen
Levent Kebapcilar
Source :
Case Reports in Oncological Medicine, Vol 2014 (2014)
Publication Year :
2014
Publisher :
Hindawi Limited, 2014.

Abstract

Hypersecretion of PTHrP is a relatively common cause of malignancy-related hypercalcemia. However, there is only one case report of letrozole induced hypercalcemia. A 52-year-old female patient was referred to our clinic because of the recent discovery of hypercalcemia (11.0 mg/dL). The patient had a history of left breast carcinoma. She had started a course of letrozole (aromatase inhibitor; 2.5 mg dose/day) ten months earlier. Patient’s parathyroid hormone-related protein levels were normal and a bone scintigram revealed no evidence of skeletal metastasis. Other potential causes of high calcium levels were ruled out. We recognized that, when letrozole was taken at one dose daily (2.5 mg), she had recurrent hypercalcemia. Our experience suggests that letrozole may precipitate hypercalcemia in a patient with breast cancer.

Details

Language :
English
ISSN :
20906706 and 20906714
Volume :
2014
Database :
Directory of Open Access Journals
Journal :
Case Reports in Oncological Medicine
Publication Type :
Academic Journal
Accession number :
edsdoj.0aafa6f2ead641a2b0cf2ca2cbb12e1a
Document Type :
article
Full Text :
https://doi.org/10.1155/2014/608585